Less stringent requirements in pharmaceuticals and biotechnology could help biotechs by prompting accelerated drug approvals.
A stock sale and confusion regarding its parent company are factors dragging down the stock.
Any euphoria after the biotech stock's big jump yesterday didn't last long.
/PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to...
The company is walling off subsidiary Scilex from its bankruptcy proceedings.
/PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to...
A bankruptcy filing is weighing on the drugmaker's shares today.
Wall Street is bullish on these two beaten-down healthcare stocks.
Sorrento Therapeutics: Q3 Earnings Snapshot
The drugmaker's stock is moving upward today in sympathy with the broader biopharmaceutical industry.